Lyapunov exponents and phase diagrams reveal multi-factorial control over TRAIL-induced apoptosis

Receptor‐mediated apoptosis proceeds via two pathways: one requiring only a cascade of initiator and effector caspases (type I behavior) and the second requiring an initiator–effector caspase cascade and mitochondrial outer membrane permeabilization (type II behavior). Here, we investigate factors controlling type I versus II phenotypes by performing Lyapunov exponent analysis of an ODE‐based model of cell death. The resulting phase diagrams predict that the ratio of XIAP to pro‐caspase‐3 concentrations plays a key regulatory role: type I behavior predominates when the ratio is low and type II behavior when the ratio is high. Cell‐to‐cell variability in phenotype is observed when the ratio is close to the type I versus II boundary. By positioning multiple tumor cell lines on the phase diagram we confirm these predictions. We also extend phase space analysis to mutations affecting the rate of caspase‐3 ubiquitylation by XIAP, predicting and showing that such mutations abolish all‐or‐none control over activation of effector caspases. Thus, phase diagrams derived from Lyapunov exponent analysis represent a means to study multi‐factorial control over a complex biochemical pathway.

[1]  P. Scheurich,et al.  Segregation of APO‐1/Fas antigen‐ and tumor necrosis factor receptor‐mediated apoptosis , 1994, European journal of immunology.

[2]  O. Wolkenhauer,et al.  Thresholds in transient dynamics of signal transduction pathways. , 2010, Journal of theoretical biology.

[3]  D. Vaux,et al.  Determination of cell survival by RING-mediated regulation of inhibitor of apoptosis (IAP) protein abundance. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[4]  D. Lauffenburger,et al.  Quantitative analysis of pathways controlling extrinsic apoptosis in single cells. , 2008, Molecular cell.

[5]  M. Peter,et al.  Differences between CD95 type I and II cells detected with the CD95 ligand. , 1999, Cell death and differentiation.

[6]  Guy S. Salvesen,et al.  X-linked IAP is a direct inhibitor of cell-death proteases , 1997, Nature.

[7]  H. Walczak,et al.  Is TRAIL the holy grail of cancer therapy? , 2009, Apoptosis.

[8]  R A Knight,et al.  Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes , 2009, Cell Death and Differentiation.

[9]  Yigong Shi,et al.  Molecular mechanisms of caspase regulation during apoptosis , 2004, Nature Reviews Molecular Cell Biology.

[10]  K. Kinzler,et al.  X-linked inhibitor of apoptosis protein (XIAP) is a nonredundant modulator of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in human cancer cells. , 2004, Cancer research.

[11]  T. Wilson,et al.  Combined inhibition of FLIP and XIAP induces Bax-independent apoptosis in type II colorectal cancer cells , 2009, Oncogene.

[12]  P. Sorger,et al.  Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis , 2009, Nature.

[13]  Yili Yang,et al.  Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. , 2000, Science.

[14]  C. Ceccarini,et al.  Some paradoxical effects of inhibitors of protein synthesis on protein turnover in cultured human cells , 1976, In Vitro.

[15]  D. Lauffenburger,et al.  Modeling a Snap-Action, Variable-Delay Switch Controlling Extrinsic Cell Death , 2008, PLoS biology.

[16]  F. Allgöwer,et al.  Bistability Analyses of a Caspase Activation Model for Receptor-induced Apoptosis* , 2004, Journal of Biological Chemistry.

[17]  M. Peter,et al.  Differences between CD95 type I and type II cells detected with the CD95 ligand [1] , 1999 .

[18]  Ingo Schmitz,et al.  Differential Modulation of Apoptosis Sensitivity in CD95 Type I and Type II Cells* , 1999, The Journal of Biological Chemistry.

[19]  Maike A. Laussmann,et al.  The Caspase-8 Dimerization/Dissociation Balance Is a Highly Potent Regulator of Caspase-8, -3, -6 Signaling* , 2010, The Journal of Biological Chemistry.

[20]  Alicia Algeciras-Schimnich,et al.  Two CD95 tumor classes with different sensitivities to antitumor drugs , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[21]  L. Penrose,et al.  THE CORRELATION BETWEEN RELATIVES ON THE SUPPOSITION OF MENDELIAN INHERITANCE , 2022 .

[22]  Ingo Schmitz,et al.  The Role of c-FLIP in Modulation of CD95-induced Apoptosis* , 1999, The Journal of Biological Chemistry.

[23]  G. Salvesen,et al.  Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family , 2006, EMBO reports.

[24]  G. Savich,et al.  Smac/DIABLO release from the mitochondria and XIAP inhibition are essential to limit clonogenicity of Type I tumor cells after TRAIL receptor stimulation , 2010 .

[25]  Wafik S El-Deiry,et al.  Defining characteristics of Types I and II apoptotic cells in response to TRAIL. , 2002, Neoplasia.

[26]  G. Vinnicombe,et al.  Fundamental limits on the suppression of molecular fluctuations , 2010, Nature.

[27]  D. Green,et al.  Inducible Dimerization and Inducible Cleavage Reveal a Requirement for Both Processes in Caspase-8 Activation* , 2010, The Journal of Biological Chemistry.

[28]  K. Jaqaman,et al.  Robust single particle tracking in live cell time-lapse sequences , 2008, Nature Methods.

[29]  G M Cohen,et al.  XIAP inhibition of caspase-3 preserves its association with the Apaf-1 apoptosome and prevents CD95- and Bax-induced apoptosis , 2002, Cell Death and Differentiation.

[30]  Malabika Sarker,et al.  SPOTS: signaling protein oligomeric transduction structures are early mediators of death receptor-induced apoptosis at the plasma membrane. , 2004, The Journal of cell biology.

[31]  Stephanie Birkey Reffey,et al.  Characterization of XIAP-Deficient Mice , 2001, Molecular and Cellular Biology.

[32]  M. Peter,et al.  The CD95 type I/type II model. , 2003, Seminars in immunology.

[33]  Peter Schow,et al.  Tumor-cell resistance to death receptor–induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax , 2002, Nature Medicine.

[34]  Jochen H M Prehn,et al.  Systems analysis of effector caspase activation and its control by X‐linked inhibitor of apoptosis protein , 2006, The EMBO journal.

[35]  C. Hallas,et al.  The role of receptor internalization in CD95 signaling , 2006, The EMBO journal.

[36]  J. Tavaré,et al.  Rapid caspase‐3 activation during apoptosis revealed using fluorescence‐resonance energy transfer , 2000, EMBO reports.

[37]  M. Butterworth,et al.  Bcl-2 and Bcl-xL Inhibit CD95-mediated Apoptosis by Preventing Mitochondrial Release of Smac/DIABLO and Subsequent Inactivation of X-linked Inhibitor-of-Apoptosis Protein* , 2002, The Journal of Biological Chemistry.

[38]  J. D. Robertson,et al.  Caspase-9 Activation by the Apoptosome Is Not Required for Fas-mediated Apoptosis in Type II Jurkat Cells* , 2009, The Journal of Biological Chemistry.

[39]  G. Cohen,et al.  Proteasome-mediated Degradation of Smac during Apoptosis: XIAP Promotes Smac Ubiquitination in Vitro * , 2002, The Journal of Biological Chemistry.

[40]  D. Lauffenburger,et al.  Physicochemical modelling of cell signalling pathways , 2006, Nature Cell Biology.

[41]  A. Letai,et al.  Diagnosing and exploiting cancer's addiction to blocks in apoptosis , 2008, Nature Reviews Cancer.

[42]  M. Diaz,et al.  Surviving apoptosis: a possible mechanism of benzene-induced leukemia. , 2005, Chemico-biological interactions.

[43]  H. Steller,et al.  Regulation of apoptosis by XIAP ubiquitin-ligase activity. , 2008, Genes & development.

[44]  Christoph Borner,et al.  XIAP discriminates between type I and type II FAS-induced apoptosis , 2009, Nature.

[45]  D. Lauffenburger,et al.  Direct Lyapunov exponent analysis enables parametric study of transient signalling governing cell behaviour. , 2006, Systems biology.

[46]  P. Chaney,et al.  SURVIVING , 1976, Nursing.

[47]  C. Belka,et al.  Type I and type II reactions in TRAIL-induced apoptosis – results from dose–response studies , 2005, Oncogene.

[48]  M. Rehm,et al.  Dynamics of outer mitochondrial membrane permeabilization during apoptosis , 2009, Cell Death and Differentiation.

[49]  R. Fisher XV.—The Correlation between Relatives on the Supposition of Mendelian Inheritance. , 1919, Transactions of the Royal Society of Edinburgh.

[50]  D. Lauffenburger,et al.  A Compendium of Signals and Responses Triggered by Prodeath and Prosurvival Cytokines*S , 2005, Molecular & Cellular Proteomics.

[51]  John Calvin Reed,et al.  X-linked Inhibitor of Apoptosis Protein (XIAP) Inhibits Caspase-3 and -7 in Distinct Modes* , 2001, The Journal of Biological Chemistry.

[52]  Mark H Ellisman,et al.  Disruption of Mitochondrial Function during Apoptosis Is Mediated by Caspase Cleavage of the p75 Subunit of Complex I of the Electron Transport Chain , 2004, Cell.

[53]  A. Vaughan,et al.  Surviving apoptosis , 2004, Apoptosis.

[54]  George Haller,et al.  Optimal pollution mitigation in Monterey Bay based on coastal radar data and nonlinear dynamics. , 2007, Environmental science & technology.

[55]  M. Peter,et al.  Two CD95 (APO‐1/Fas) signaling pathways , 1998, The EMBO journal.